CDKN2A and acute lymphoblastic leukemia: We noticed a significant difference in FIP1L1 (p = 0.015), LEF1 (p = 0.007), MTAP (p = 0.005), and CDKN2A (p = 0.016) deletion frequencies in the high-risk group of T-ALL patients in comparison to non-high-risk group (p < 0.05).